Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about ABCL, unsubscribe in one click. Privacy
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Bamlanivimab (LY3819253) | COVID-19 | Phase 3 · NCT04497987 | Completed |
| Etesevimab | COVID-19 | Phase 3 · NCT04497987 | Completed |
| Bebtelovimab (LY3853113) | COVID-19 | Phase 2/3 · NCT04427501 | Completed |
| ABCL635 | Vasomotor Symptoms Associated With Menopause | Phase 1/2 · NCT07118891 | Active not recruiting |
| Sotrovimab (VIR-7831) | COVID-19 | Phase 2 · NCT04634409 | Completed |
| ABCL575 | Healthy Volunteers | Phase 1 · NCT07108894 | Active not recruiting |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
ABCL holds $540.1M in cash and short-term investments (as of Jun 30, 2026) and burns about $3.8M/quarter from operations, an estimated runway of 426.4 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 0 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ABCL files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Carl L. G. Hansen Chief Executive Officer, Director, 10% o · +32.35M options |
Insider | 56,984,009 | 18.59% | 2024-11-25 |
| Thermopylae Holdings Ltd. 10% owner |
Insider | 56,134,097 | 18.31% | 2026-02-27 |
| Baker Bros. Advisors LP | Institution (13G, 5%+) | 33,012,138 | 10.77% | 2026-04-30 |
| Veronique Lecault Chief Technology Officer, Director · +13.69M options |
Insider | 2,458,666 | 0.80% | 2024-06-21 |
| Michael R Hayden Director · +1.91M options |
Insider | 1,491,642 | 0.49% | 2026-08-24 |
| Stephen Quake Director · +501,565 options |
Insider | 1,100,436 | 0.36% | 2025-11-10 |
| Andrew Booth Chief Financial Officer · +16.69M options |
Insider | 613,759 | 0.20% | 2026-08-14 |
| John S. Montalbano Director · +2.17M options |
Insider | 256,000 | 0.08% | 2026-08-18 |
Share count 306,611,466 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ABCL and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →